<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02897817</url>
  </required_header>
  <id_info>
    <org_study_id>APRim</org_study_id>
    <nct_id>NCT02897817</nct_id>
  </id_info>
  <brief_title>Treatment Adherence to Injectable Methotrexate in Rheumatoid Arthritis</brief_title>
  <acronym>APRim</acronym>
  <official_title>Treatment Adherence in Patients With Rheumatoid Arthritis Previously Treated With Oral or Injectable Methotrexate and Requiring a New Treatment With Injectable Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Pharma SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordic Pharma SAS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate, at 6 months, the rate of patients whose adherence to
      injectable MTX remained strong or improved according to patient-reported outcome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients whose adherence to methotrexate (MTX) remained strong or improved between inclusion (V0) and follow-up (V1) at 6 months.</measure>
    <time_frame>6 months</time_frame>
    <description>Patient adherence is measured via the Morisky score at V0 and V1, using patient-reported outcome (PRO).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of patient adherence between the 2 cohorts.</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Analysis of improved or equivalent patient adherence as assessed by the Morisky score at V0 and V1 between the 2 cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for non-adherence given by patients after 6 months.</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Assessed in the overall patient population and between the 2 cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global and functional patient satisfaction with treatment after 6 months as assessed by the Likert scale for global satisfaction.</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Global patient satisfaction will be assessed in the overall patient population and between the 2 cohorts using the Likert scale (1 to 5 rating).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global and functional patient satisfaction with treatment after 6 months as assessed by the Disease Activity Score 28 (DAS28) for disease severity.</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Patient satisfaction will be assessed in the overall patient population and between the 2 cohorts using the DAS28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global and functional patient satisfaction with treatment after 6 months as assessed by the Health Assessment Questionnaire Disability Index (HAQ-DI) for functional disability.</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Patient satisfaction will be assessed in the overall patient population and between the 2 cohorts using the HAQ-DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global and functional patient satisfaction with treatment after 6 months as assessed by the Echelle de Mesure de l'Impact de la polyarthrite Rhumato√Øde (EMIR) for quality of life.</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Patient satisfaction will be assessed in the overall patient population and between the 2 cohorts using the EMIR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of improvement or maintenance of patient adherence, as evaluated by the change in the Morisky scores at V0 and V1, based on family situation.</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Identification of factors associated with the improvement or maintenance of adherence in the overall patient population and between the 2 cohorts by assessing family situation. Adherence is evaluated by the change in the Morisky scores at V0 and V1, with a score of 0 considered as strong adherence and a score &gt;0 considered as non-adherence. Patient adhesion is classified as remaining strong if the Morisky score at V0 and V1 remains at 0 and patient adhesion is classified as improved if the Morisky score at V0 is greater than 0 (non-adherent) while the score at V1 is 0 (strong adherence).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of improvement or maintenance of patient adherence, as evaluated by the change in the Morisky scores at V0 and V1, based on socio-professional standing.</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Identification of factors associated with the improvement or maintenance of adherence in the overall patient population and between the 2 cohorts by assessing socio-professional standing. Adherence is evaluated by the change in the Morisky scores at V0 and V1, with a score of 0 considered as strong adherence and a score &gt;0 considered as non-adherence. Patient adhesion is classified as remaining strong if the Morisky score at V0 and V1 remains at 0 and patient adhesion is classified as improved if the Morisky score at V0 is greater than 0 (non-adherent) while the score at V1 is 0 (strong adherence).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of improvement or maintenance of patient adherence, as evaluated by the change in the Morisky scores at V0 and V1, based on age.</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Identification of factors associated with the improvement or maintenance of adherence in the overall patient population and between the 2 cohorts by assessing age. Adherence is evaluated by the change in the Morisky scores at V0 and V1, with a score of 0 considered as strong adherence and a score &gt;0 considered as non-adherence. Patient adhesion is classified as remaining strong if the Morisky score at V0 and V1 remains at 0 and patient adhesion is classified as improved if the Morisky score at V0 is greater than 0 (non-adherent) while the score at V1 is 0 (strong adherence).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of improvement or maintenance of patient adherence, as evaluated by the change in the Morisky scores at V0 and V1, based on comorbidities.</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Identification of factors associated with the improvement or maintenance of adherence in the overall patient population and between the 2 cohorts by assessing comorbidities. Adherence is evaluated by the change in the Morisky scores at V0 and V1, with a score of 0 considered as strong adherence and a score &gt;0 considered as non-adherence. Patient adhesion is classified as remaining strong if the Morisky score at V0 and V1 remains at 0 and patient adhesion is classified as improved if the Morisky score at V0 is greater than 0 (non-adherent) while the score at V1 is 0 (strong adherence).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of improvement or maintenance of patient adherence, as evaluated by the change in the Morisky scores at V0 and V1, based on the co-administration of other injectable treatments.</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Identification of factors associated with the improvement or maintenance of adherence in the overall patient population and between the 2 cohorts by assessing the co-administration of other injectable treatments (binary variable). Adherence is evaluated by the change in the Morisky scores at V0 and V1, with a score of 0 considered as strong adherence and a score &gt;0 considered as non-adherence. Patient adhesion is classified as remaining strong if the Morisky score at V0 and V1 remains at 0 and patient adhesion is classified as improved if the Morisky score at V0 is greater than 0 (non-adherent) while the score at V1 is 0 (strong adherence).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of improvement or maintenance of patient adherence, as evaluated by the change in the Morisky scores at V0 and V1, based on the reasons for the switch to new MTX injection device.</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Identification of factors associated with the improvement or maintenance of adherence in the overall patient population and between the 2 cohorts by assessing the reasons for the switch to new MTX injection device. Adherence is evaluated by the change in the Morisky scores at V0 and V1, with a score of 0 considered as strong adherence and a score &gt;0 considered as non-adherence. Patient adhesion is classified as remaining strong if the Morisky score at V0 and V1 remains at 0 and patient adhesion is classified as improved if the Morisky score at V0 is greater than 0 (non-adherent) while the score at V1 is 0 (strong adherence).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of improvement or maintenance of patient adherence, as evaluated by the change in the Morisky scores at V0 and V1, based on rheumatoid arthritis severity (assessed by DAS28).</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Identification of factors associated with the improvement or maintenance of adherence in the overall patient population and between the 2 cohorts by assessing rheumatoid arthritis severity (assessed by DAS28). Adherence is evaluated by the change in the Morisky scores at V0 and V1, with a score of 0 considered as strong adherence and a score &gt;0 considered as non-adherence. Patient adhesion is classified as remaining strong if the Morisky score at V0 and V1 remains at 0 and patient adhesion is classified as improved if the Morisky score at V0 is greater than 0 (non-adherent) while the score at V1 is 0 (strong adherence).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of improvement or maintenance of patient adherence, evaluated by the change in the Morisky scores at V0 and V1, based on patient functional handicap (assessed by the HAQ-DI).</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Identification of factors associated with the improvement or maintenance of adherence in the overall patient population and between the 2 cohorts by assessing functional handicap (assessed by the HAQ-DI). Adherence is evaluated by the change in the Morisky scores at V0 and V1, with a score of 0 considered as strong adherence and a score &gt;0 considered as non-adherence. Patient adhesion is classified as remaining strong if the Morisky score at V0 and V1 remains at 0 and patient adhesion is classified as improved if the Morisky score at V0 is greater than 0 (non-adherent) while the score at V1 is 0 (strong adherence).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of improvement or maintenance of patient adherence, as evaluated by the Morisky score at V0 and V1, based on global patient satisfaction (assessed by Likert scale results).</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Identification of factors associated with the improvement or maintenance of adherence in the overall patient population and between the 2 cohorts by assessing global patient satisfaction (assessed by Likert scale results). Adherence is evaluated by the change in the Morisky scores at V0 and V1, with a score of 0 considered as strong adherence and a score &gt;0 considered as non-adherence. Patient adhesion is classified as remaining strong if the Morisky score at V0 and V1 remains at 0 and patient adhesion is classified as improved if the Morisky score at V0 is greater than 0 (non-adherent) while the score at V1 is 0 (strong adherence).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of improvement or maintenance of patient adherence, evaluated by the change in the Morisky scores at V0 and V1, based on whether the injection was self-administered or administered by a third party.</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Identification of factors associated with the improvement or maintenance of adherence in the overall patient population and between the 2 cohorts by assessing whether the injection was self-administered or administered by a third party. Adherence is evaluated by the change in the Morisky scores at V0 and V1, with a score of 0 considered as strong adherence and a score &gt;0 considered as non-adherence. Patient adhesion is classified as remaining strong if the Morisky score at V0 and V1 remains at 0 and patient adhesion is classified as improved if the Morisky score at V0 is greater than 0 (non-adherent) while the score at V1 is 0 (strong adherence).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of improvement or maintenance of patient adherence, evaluated by the change in the Morisky scores at V0 and V1, based on tolerability and level of patient trust with HCP (assessed by Likert scale results).</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Identification of factors associated with the improvement or maintenance of adherence in the overall patient population and between the 2 cohorts by assessing tolerability and level of patient trust with HCP (assessed by Likert scale results). Adherence is evaluated by the change in the Morisky scores at V0 and V1, with a score of 0 considered as strong adherence and a score &gt;0 considered as non-adherence. Patient adhesion is classified as remaining strong if the Morisky score at V0 and V1 remains at 0 and patient adhesion is classified as improved if the Morisky score at V0 is greater than 0 (non-adherent) while the score at V1 is 0 (strong adherence).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doctor satisfaction with the treatment after 6 months.</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Assessed in the overall patient population and between the 2 cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence, evaluated by the Morisky score at 6 months, as assessed by the HCP compared to the treatment adherence as reported by the patient .</measure>
    <time_frame>6 months after inclusion.</time_frame>
    <description>Treatment adherence is measured via the Morisky score at V0 and V1.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">471</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Oral to Injectable</arm_group_label>
    <description>Patients treated with oral MTX and requiring a switch to injectable MTX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injectable to Injectable</arm_group_label>
    <description>Patients treated with injectable MTX and eligible for a change in MTX injection device.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        RA patients currently treated with oral methotrexate (MTX) and requiring a switch to
        injectable MTX or currently treated with an injectable MTX and eligible for a change to a
        different MTX injection device will be asked to participate from RA treatment change
        (inclusion visit) up to 6 months after inclusion.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (‚â• 18 years old)

          -  Patients with a diagnosis of RA as confirmed by the ACR/EULAR (2010) Classification
             Criteria for Rheumatoid Arthritis

          -  Patients:

               -  currently treated with oral MTX and requiring a switch to an injectable MTX* or

               -  currently treated with an injectable MTX* and eligible for a change of MTX
                  injection device*

          -  Patients informed about and accepting the computer processing of their medical data
             and their right of accesss and correction.

        Exclusion Criteria:

        - Patients who refuse to participate in the study or are unable to fill out the patient
        diary.

        *On the basis of the products marketed at the time of submission of the study to Oversight
        Authorities (M√©thotrexate Biodim¬Æ, Metoject¬Æ and imeth¬Æ).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ren√©-Marc FLIPO, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU H√¥pital Roger Salengro, LILLE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric SENBEL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Doctor's Office, MARSEILLE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sonia TROPE, Nurse</last_name>
    <role>Principal Investigator</role>
    <affiliation>ANDAR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H√©l√®ne HERMAN-DEMARS, MD</last_name>
    <role>Study Director</role>
    <affiliation>NORDIC PHARMA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nordic Pharma</name>
      <address>
        <city>Paris</city>
        <zip>75007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Methotrexate</keyword>
  <keyword>Treatment adherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

